289 related articles for article (PubMed ID: 28336575)
21. Naloxegol for managing opioid-induced constipation.
Shelton KN; Clements JN
JAAPA; 2017 Sep; 30(9):51-53. PubMed ID: 28858018
[TBL] [Abstract][Full Text] [Related]
22. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.
van Malderen K; Halawi H; Camilleri M
Neurogastroenterol Motil; 2018 May; 30(5):e13250. PubMed ID: 29119706
[TBL] [Abstract][Full Text] [Related]
23. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation.
Webster L; Diva U; Tummala R; Sostek M
Pain Pract; 2018 Apr; 18(4):505-514. PubMed ID: 28898536
[TBL] [Abstract][Full Text] [Related]
24. Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation.
Al-Huniti N; Nielsen JC; Hutmacher MM; Lappalainen J; Cantagallo K; Sostek M
CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):359-66. PubMed ID: 27435972
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
Gottfridsson C; Carlson G; Lappalainen J; Sostek M
Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
[TBL] [Abstract][Full Text] [Related]
27. Acute opioid withdrawal syndrome from naloxone/naloxegol interaction.
Olmo M; González-Barboteo J; Moreno D; Coma E; Serrano G
BMJ Support Palliat Care; 2021 Dec; 11(4):408-410. PubMed ID: 32788278
[TBL] [Abstract][Full Text] [Related]
28. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.
Lemaire A; Pointreau Y; Narciso B; Piloquet FX; Braniste V; Sabaté JM
Support Care Cancer; 2021 Dec; 29(12):7577-7586. PubMed ID: 34120247
[TBL] [Abstract][Full Text] [Related]
30. Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.
Al-Huniti N; Zhou D; Xu H; Aksenov S; Bui KH; Fox R; Helmlinger G; Stanski D
Clin Pharmacol Ther; 2017 Nov; 102(5):741-744. PubMed ID: 28548207
[TBL] [Abstract][Full Text] [Related]
31. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.
Streicher JM; Bilsky EJ
J Pharm Pract; 2018 Dec; 31(6):658-669. PubMed ID: 28946783
[TBL] [Abstract][Full Text] [Related]
32. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.
Lawson R; King F; Marsh K; Altincatal A; Cimen A
Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744
[TBL] [Abstract][Full Text] [Related]
33. ▼Naloxegol for opioid-induced constipation.
Drug Ther Bull; 2015 Dec; 53(12):138-40. PubMed ID: 26660436
[TBL] [Abstract][Full Text] [Related]
34. Treating Opioid-Induced Constipation in Older Adults: New Options.
Sani H; Mahan RJ
Consult Pharm; 2015 Oct; 30(10):612-5. PubMed ID: 26450143
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms that underlie μ-opioid receptor agonist-induced constipation: differential involvement of μ-opioid receptor sites and responsible regions.
Mori T; Shibasaki Y; Matsumoto K; Shibasaki M; Hasegawa M; Wang E; Masukawa D; Yoshizawa K; Horie S; Suzuki T
J Pharmacol Exp Ther; 2013 Oct; 347(1):91-9. PubMed ID: 23902939
[TBL] [Abstract][Full Text] [Related]
36. Differences in the morphine-induced inhibition of small and large intestinal transit: Involvement of central and peripheral μ-opioid receptors in mice.
Matsumoto K; Umemoto H; Mori T; Akatsu R; Saito S; Tashima K; Shibasaki M; Kato S; Suzuki T; Horie S
Eur J Pharmacol; 2016 Jan; 771():220-8. PubMed ID: 26712376
[TBL] [Abstract][Full Text] [Related]
37. Naloxegol to Treat Constipation in a Patient Taking Opioids for Cancer Pain: A Case Report.
Gálvez R; Maire C; Tovar I; Vargas P
A A Pract; 2018 Jul; 11(1):22-24. PubMed ID: 29634552
[TBL] [Abstract][Full Text] [Related]
38. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
Webster L; Tummala R; Diva U; Lappalainen J
J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
[TBL] [Abstract][Full Text] [Related]
39. Evaluating naloxegol for the treatment of opioid-induced constipation.
Daniali M; Nikfar S; Abdollahi M
Expert Opin Pharmacother; 2020 Jun; 21(8):883-891. PubMed ID: 32129103
[TBL] [Abstract][Full Text] [Related]
40. Consumption of Movantik™ (Naloxegol) results in detection of naloxone in the patient's urine evaluated by confirmatory urine drug testing.
Haidari M; Mansani S; Ponds D; Romero L; Alsaab S
Clin Biochem; 2019 May; 67():48-53. PubMed ID: 30890414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
